|
|
Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication
Manon Allaire
,
Pierre Nahon
,
Richard Layese
,
Valérie Bourcier
,
Carole Cagnot
,
et al.
Article dans une revue
hal-02648452v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis
Pierre Nahon
,
Jessica Bamba-Funck
,
Richard Layese
,
Eric Trépo
,
Jessica Zucman-Rossi
,
et al.
Article dans une revue
hal-03883705v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
ABO blood group does not influence Child‐Pugh A cirrhosis outcome: An observational study from CIRRAL and ANRS CO12 CIRVIR cohorts
Isabelle Ollivier-Hourmand
,
Yohann Repesse
,
Pierre Nahon
,
Cendrine Chaffaut
,
Thông Dao
,
et al.
Article dans une revue
hal-03553907v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study
Tarik Asselah
,
Stanislas Pol
,
Christophe Hezode
,
Veronique Loustaud-Ratti
,
Vincent Leroy
,
et al.
Article dans une revue
hal-03590858v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Efficacy and Safety of Elbasvir/Grazoprevir for 8 or 12 Weeks in Participants with Hepatitis C Virus Genotype 4 Infection
Tarik Asselah
,
Stanislas Pol
,
Christophe Hezode
,
Veronique Loustaud Ratti
,
Vincent Leroy
,
et al.
Hepatology, 2018, 68 (1), pp.385A
Article dans une revue
hal-03590861v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|